Alterity Therapeutics Lim... (ATHE)
NASDAQ: ATHE
· Real-Time Price · USD
4.83
-0.18 (-3.59%)
At close: Oct 16, 2025, 3:59 PM
4.88
1.03%
After-hours: Oct 16, 2025, 07:40 PM EDT
-3.59% (1D)
| Bid | 4.76 |
| Market Cap | 43.78M |
| Revenue (ttm) | 5.44M |
| Net Income (ttm) | -12.15M |
| EPS (ttm) | -0.74 |
| PE Ratio (ttm) | -6.53 |
| Forward PE | -5.5 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 5 |
| Volume | 30,890 |
| Avg. Volume (20D) | 135,278 |
| Open | 4.92 |
| Previous Close | 5.01 |
| Day's Range | 4.82 - 5.02 |
| 52-Week Range | 1.00 - 7.00 |
| Beta | 0.32 |
| Ex-Dividend Date | n/a |
About ATHE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ATHE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ATHE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-14.81%
Alterity Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
5 months ago
+26.45%
Alterity Therapeutics shares are trading higher after the company announced that the FDa granted it Fast Track designation for ATH434 for the treatment of Multiple System Atrophy.
